Edward B. Garon, MD, discusses data from the IMpower150 trial where patients with <em>EGFR-</em>mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.
Edward B. Garon, MD, director of thoracic oncology at the David Geffen School of Medicine at UCLA, discusses data from the IMpower150 trial where patients withEGFR-mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.
Garon says the quadruplet regimen held the most benefit in respect to progression-free survival and also suggested an advantage in overall survival as well, despite a hazard ratio over 1. However, there was no clear benefit when atezolizumab was substituted for bevacizumab.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More